Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Releases Preclinical Data Showing Efficacy of TTR Amyloidosis Rx Candidate

Premium

Alnylam Pharmaceuticals this week released new preclinical data showing that its TTR amyloidosis drug candidate could trigger dose-dependent reductions of liver TTR messenger RNA and serum TTR protein levels by more than 80 percent in transgenic mice and non-human primates.

The data also demonstrated that the silencing effects extended more than three weeks after a single dose administration, according to the company.

TTR amyloidosis is a hereditary, systemic disease caused by a mutation in the transthyretin gene. This summer, Alnylam announced that it had moved its investigational TTR amyloidosis therapeutic, ALN-TTR, into its formal drug-development pipeline (see RNAi News, 8/13/2009).

Alnylam said that it expects to begin clinical testing of the drug in early 2010.